Since we launched our first IVD test kit in 1966 our products have consistently been recognized by the market for their excellence.
We have carried out a number of successful acquisitions of best-in-class IVD companies over the years (e.g. Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010).
This has further reinforced the know-how in our group and bolstered our capacity to innovate, develop, produce and deliver products of only the highest quality.
Products by diseases and disorders:
News & EventsView all news & upcoming events
Fujirebio Europe launches iAMP® COVID-19 SANO Assay, a molecular detection assay that can be performed in saliva
OHMX.bio and Fujirebio Europe receive grant of 720K EURO to incorporate third generation sequencing into clinical in vitro diagnostics platform
Fujirebio Europe and CENTOGENE enter partnership to provide rapid and high-quality preventive SARS-CoV-2 antigen testing
Fujirebio Europe enters an agreement with ADx NeuroSciences for the commercialization of novel biomarkers
Fujirebio Europe announces CE marking of the fully automated Lumipulse® G SARS-CoV-2 antigen assay and the rapid antigen device ESPLINE® SARS-CoV-2
Fujirebio Europe launches the Lumipulse® G Aldosterone and Renin assays for fully automated quantitative determination of aldosterone and active renin
Healthcare for You.
With our deep involvement in human health, we aim to be a group that contributes to the development of healthcare through trust and innovation.
What we hold dear is the starting point for the creation of a prosperous future.
That is, the health of each and every person.
Because we have been watching over people's health for many decades, we are able to change the future of medical care and create new possibilities in healthcare.
We will continue the challenge to deliver optimal healthcare to each individual.
We will move forward, unceasingly.
Healthcare for You.
For your health, for your future happiness.
A global partner of choice
Today, we sell our products in more than 100 countries worldwide.
We have offices in the United States, Latin America, Europe and Asia, and are supported by an international distribution network and leading OEMs.
Our proven commitment to manufacturing quality has earned us a strong reputation with our direct customers, and global partners at leading diagnostic companies.
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
May 27, 2021
Since November 2020 Fujirebio Europe and CENTOGENE have partnered to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing in...
May 11, 2021
Over the last decades, biomarkers have become an extremely important tool in the care of patients with ovarian cancer. Biomarkers are capable of...
Mar 1, 2021